Rapidexon 2 mg/ml solution for injection

Authorised

- Dexamethasone sodium phosphate

Product identification

Medicine name:
Rapidexon 2 mg/ml solution for injection
Rapidexon 2 mg/ml injekcinis tirpalas

Active substance:
Dexamethasone sodium phosphate

Target species:
Horse
Cattle
Pig
Dog
Cat

Route of administration:
Intraarticular use
Intramuscular use
Intravenous use
Intrabursal use

Product details

Active substance and strength:

Dexamethasone sodium phosphate
2.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intraarticular use:

- **Horse**
  - Meat and offal. 8 day

Intramuscular use:

- **Cattle**
  - Milk. 72 hour
  - Meat and offal. 8 day
- **Pig**
  - Meat and offal. 2 day
- **Horse**
  - Meat and offal. 8 day
- **Dog**
- **Cat**

Intravenous use:

- **Horse**
  - Meat and offal. 8 day

Intrabursal use:

-

Horse

- Meat and offal. 8 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QH02AB02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Lithuania

Package description:
50 ml vial glass type I uncoloured with bromobutyl rubber stopper type I secured with aluminium cap
25 ml vial (filled in 30 ml vial) glass type I uncoloured with bromobutyl rubber stopper type I secured with aluminium cap
100 ml vial glass type I uncoloured with bromobutyl rubber stopper type I secured with aluminium

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Eurovet Animal Health B.V.

Marketing authorisation date:
25/03/2008

Manufacturing sites for batch release:

Eurovet Animal Health B.V.

Responsible authority:
State Food And Veterinary Service

Authorisation number:
LT/2/08/1787/001-003

Date of authorisation status change:
30/07/2011

Reference member state:
Netherlands

Procedure number:
NL/V/0284/001

Concerned member states:
Austria Belgium Czechia Denmark Finland France Greece Hungary Ireland Lithuania Poland Portugal Slovakia Slovenia Spain
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

RV1787.pdf

Rapidexon 2 mg.pdf
